Low Grade Glioma Relapse / Refractory
Low Grade Glioma Relapse / Refractory
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
- Ages: 1 year and ≤ 30 years old
This phase I/II trial studies the side effects and best dose of adding hydroxychloroquine to dabrafenib and/or trametinib, and to see how well they work in treating children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) ...More
ACCL2031: A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
- Ages: 4 Years to 17 Years
This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or has come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make ...More
APEC1621: Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders
- Ages: 12 Months to 21 Years
PURPOSE: This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/o ...More
GO42286: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors
- Ages: Up to 17 years
This study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available. GO42286: A Phase I/II, ...More
PEPN2111: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Ages: 1 Month to 30 Years
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block sig ...More
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
- Ages: 6 Months to 18 Years
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors. In this study, we will test the combination of atezolizumab with chemotherap ...More
Contact Us
To learn more about available clinical trials related to brain and spinal tumors, contact us at cancer@cchmc.org or 513-636-2799.
Related Studies
- Medulloblastoma New Diagnosis
- Medulloblastoma Relapse / Refractory
- Low Grade Glioma New Diagnosis
- DIPG/High Grade Glioma New Diagnosis
- DIPG/High Grade Glioma Relapse / Refractory
- Ependymoma New Diagnosis
- Ependymoma Relapse / Refractory
- Neurofibromatosis Sarcoma New Diagnosis
- Neurofibromatosis Sarcoma Relapse / Refractory
- Neurofibromatosis NF2
- Neurofibromatosis Plexiform Neurofibroma
- Neurofibromatosis OPG/Low Grade Glioma
- Neurofibromatosis Other
- ATRT
- Craniopharyngioma
- Germ Cell Tumor
- Choroid Plexus Tumor
- All Other Brain and Spinal Tumors
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
